History
A list of downloadable documents created during development.
Background information
-
-
TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: appendix A - GE decision paper - April 2015
-
-
-
Appendix A - provisional matrix of stakeholders
-
-
Appendix B - proposal paper presented to the Institute's Guidance Executive
-
Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 873 KB)
-
-
Download PDF version
-
2011/047 NICE guidance extends recommendations on Alzheimer's drugs (PDF 89 KB)
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): EIA form for guidance development
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): EIA form for guidance development
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): final appraisal determination
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): final appraisal determination
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): response to comments on the appraisal consultation
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments on the appraisal consultation
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Eisai/Pfizer
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Lundbeck
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the executable model from Lundbeck
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Novartis
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Shire
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Alzheimer's Society
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Association of British Neurologists
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from British Geriatrics Society
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Royal College of Nursing
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Royal College of Psychiatrists
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): expert comment on the appraisal consultation from Dr Peter Connelly
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments on the ACD received through the NICE website
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): evaluation report
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): a systematic review and economic model A
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): a systematic review and economic model B
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): additional analysis for PenTAG
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): PenTAG new results
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): PenTAGs parameters in the Lundbeck model
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): consultee and commentator comments on the assessment report
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from the Research Institute for the Care of Older People
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from Shire
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from Novartis
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from NHS Quality Improvement Scotland
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from NHS West Kent
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): commments from the Alzheimer's Society
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from Eisai Ltd/Pfizer Ltd (joint response)
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Lundbeck
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): non-manufacturer submission
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Alzheimer's Society (part 1)
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): British Geriatrics Society
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Royal College of Psychiatrists
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): manufacturer full submissions
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Eisai Ltd/Pfizer Ltd (joint submission)
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Lundbeck UK
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Shire Pharmaceuticals
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): response from Peninsula Technology Assessment Group (PenTAG)
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): expert written personal statements
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Connelly
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Hill
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Hill (PDF 54 KB)
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Simmons
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): overview
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report (part 1)
-
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report (part 2)
-
Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final protocol
-
Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final protocol
-
Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final matrix
-
Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final matrix
-
Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final scope
-
Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final scope
-
Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the provisional matrix
-
Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the provisional matrix
-
Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the draft scope
-
Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the draft scope
-
Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): provisional matrix
-
Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): provisional matrix
-
Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): draft scope
-
Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): draft scope
-